PMID- 20631481
OWN - NLM
STAT- MEDLINE
DCOM- 20101216
LR  - 20220311
IS  - 1423-0240 (Electronic)
IS  - 0378-584X (Linking)
VI  - 33
IP  - 7
DP  - 2010
TI  - Amphiregulin and epiregulin expression in colorectal carcinoma and the 
      correlation with clinicopathological characteristics.
PG  - 353-8
LID - 10.1159/000315380 [doi]
AB  - BACKGROUND: Amphiregulin (AREG) and epiregulin (EREG) have been found to play 
      pivotal roles in several malignancies. However, the correlation between their 
      expression and clinicopathological factors in colorectal carcinoma (CRC) is yet 
      to be further investigated. To clarify the clinical significance of AREG and EREG 
      expression in CRC, we detected serum and tissue levels of AREG and EREG. PATIENTS 
      AND METHODS: We detected serum AREG and EREG levels by ELISA, and tissue levels 
      by immunohistochemical test in 73 patients with CRC. The correlation between each 
      independent clinicopathological characteristic and AREG and EREG levels was 
      examined. RESULTS: There was significant correlation between serum AREG level and 
      vascular invasion. There was no correlation between EREG serum level and any 
      clinicopathological characteristics. Among the 73 primary lesions, 51 were 
      AREG-positive, and 48 were EREG-positive. AREG-positive status was significantly 
      correlated with depth of tumor invasion, distant metastases, and nerve invasion. 
      EREG-positive status was significantly correlated with depth of tumor invasion 
      and distant metastases. Coexpression analysis showed that 46 patients were both 
      AREG-positive and EREG-positive. CONCLUSIONS: High serum and tissue levels of 
      AREG and high tissue level of EREG are predictors of a poor prognosis in patients 
      with CRC.
CI  - Copyright 2010 S. Karger AG, Basel.
FAU - Li, Xiao-Dong
AU  - Li XD
AD  - Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, Jiangsu Province, China.
FAU - Miao, Su-Yu
AU  - Miao SY
FAU - Wang, Guo-Liang
AU  - Wang GL
FAU - Yang, Li
AU  - Yang L
FAU - Shu, Yong-Qian
AU  - Shu YQ
FAU - Yin, Yong-Mei
AU  - Yin YM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100622
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (EGF Family of Proteins)
RN  - 0 (EREG protein, human)
RN  - 0 (Epiregulin)
RN  - 0 (Glycoproteins)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Adenocarcinoma/*pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amphiregulin
MH  - Biomarkers, Tumor/*blood
MH  - China
MH  - Colorectal Neoplasms/*pathology
MH  - Disease Progression
MH  - EGF Family of Proteins
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epidermal Growth Factor/*blood
MH  - Epiregulin
MH  - Female
MH  - Glycoproteins/*blood
MH  - Humans
MH  - Hyperplasia
MH  - Immunoenzyme Techniques
MH  - Intercellular Signaling Peptides and Proteins/*blood
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplastic Cells, Circulating
MH  - Precancerous Conditions/pathology
MH  - Prognosis
EDAT- 2010/07/16 06:00
MHDA- 2010/12/17 06:00
CRDT- 2010/07/16 06:00
PHST- 2010/07/16 06:00 [entrez]
PHST- 2010/07/16 06:00 [pubmed]
PHST- 2010/12/17 06:00 [medline]
AID - 000315380 [pii]
AID - 10.1159/000315380 [doi]
PST - ppublish
SO  - Onkologie. 2010;33(7):353-8. doi: 10.1159/000315380. Epub 2010 Jun 22.